Related Experiment Video
Updated: Jun 25, 2026

Monitoring Protein-RNA Interaction Dynamics In Vivo at High Temporal Resolution Using χCRAC
Published on: May 9, 2020
Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde
1Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Protein kinase Ciota (PKCiota) is activated by oncogenic Ras proteins and is required for K-Ras-induced transformation and colonic carcinogenesis in vivo. However, the role of PKCiota in signal transduction and oncogenesis is not clear. We recently identified a small molecule, designated 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1), that can selectively kill K-Ras mutant cancer cells and induce abnormal nuclear aggregation of PKCiota in sensitive cells but not in resistant cells. To determine the causes and biological consequences of PKCiota aggregates in the nucleus, we analyzed the effect of oncrasin-1 on proteins involved in DNA repair and RNA processing. Our results showed that oncrasin-1 treatment led to coaggregation of PKCiota and splicing factors into megaspliceosomes but had no obvious effects on the DNA repair molecule Rad51. Moreover, oncrasin-1 treatment suppressed the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells but not in resistant cells, suggesting that suppression of RNA transcription is a major effect of oncrasin-1 treatment. Studies with cultured cells or with recombinant proteins showed that oncrasin-1 can disrupt the interaction of PKCiota and cyclin-dependent protein kinase 9/cyclin T1 complex, which is known to phosphorylate the largest subunit of RNA polymerase II and is required for RNA transcription. Together, our results suggest that oncrasin-1 suppresses the function of RNA processing machinery and that PKCiota might be involved in the biological function of RNA processing complexes.
Insights
Oncrasin-1 selectively kills K-Ras cancer cells by disrupting RNA processing. This drug causes protein kinase Ciota (PKCiota) to aggregate with splicing factors, suppressing RNA transcription and affecting cell function.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oncogenic Ras proteins activate protein kinase Ciota (PKCiota), crucial for K-Ras-induced transformation and carcinogenesis.
- The precise role of PKCiota in signal transduction and oncogenesis remains unclear.
- A novel small molecule, oncrasin-1, selectively eliminates K-Ras mutant cancer cells.
Purpose of the Study:
- To elucidate the causes and biological consequences of PKCiota nuclear aggregation induced by oncrasin-1.
- To investigate the impact of oncrasin-1 on DNA repair and RNA processing pathways.
- To determine the mechanism by which oncrasin-1 affects K-Ras mutant cancer cells.
Main Methods:
- Treatment of K-Ras mutant cancer cells with oncrasin-1.
- Analysis of protein aggregation, including PKCiota and splicing factors.
- Assessment of DNA repair proteins (Rad51) and RNA polymerase II phosphorylation.
- Evaluation of reporter gene expression and protein-protein interactions.
Main Results:
- Oncrasin-1 induced coaggregation of PKCiota and splicing factors into megaspliceosomes.
- No significant effect on the DNA repair molecule Rad51 was observed.
- Suppression of RNA polymerase II phosphorylation and reporter gene expression in sensitive cells.
- Oncrasin-1 disrupted the interaction between PKCiota and the CDK9/cyclin T1 complex.
Conclusions:
- Oncrasin-1 suppresses RNA transcription by interfering with RNA processing machinery.
- PKCiota plays a role in the biological function of RNA processing complexes.
- Oncrasin-1 represents a potential therapeutic strategy targeting K-Ras mutant cancers by disrupting RNA processing.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Types of RNA
RNA Performs Diverse...

